Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UCKGX
ADC Name
ADCT-701
Synonyms
ADCT-701
   Click to Show/Hide
Organization
ADC Therapeutics (Originator);Chiome Bioscience;Synaffix
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
1.9
Structure
Antibody Name
HuBa-1-3D
  Antibody Info 
Antigen Name
Protein delta homolog 1 (DLK1)
  Antigen Info 
Payload Name
SG3199 (SC-DR002)
  Payload Info 
Therapeutic Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
BCN-HydraSpace-Val-Ala-PABC
  Linker Info 
Conjugate Type
Enzymatic Catalysis
Combination Type
uzoptirine
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Lung cancer
1 Trials
Trial ID
NCT06041516
Pancreatic cancer
1 Trials
Trial ID
NCT06041516
Unspecific solid tumor
1 Trials
Trial ID
NCT06041516
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
Click To Hide/Show 2 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Maximum Observed Concentration (Cmax) 104255.6 ng/mL
PK analysis in the rat.
 [1]
Time to Maximum Concentration (Tmax) 1 h
PK analysis in the rat.
 [1]
Excretion
Click To Hide/Show 3 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Last Quantifiable Concentration (Clast) 12515.8 ng/mL
PK analysis in the rat.
 [1]
Time of Last Quantifiable Concentration (Tlast) 504 h
PK analysis in the rat.
 [1]
Elimination Half-Life (t1/2) 279.1 h
PK analysis in the rat.
 [1]
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT06041516
PHASE1
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Eligible participants must have histologically confirmed neuroendocrine neoplasms or adrenocortical carcinoma (ACC) with measurable disease (RECIST 1.1), prior standard therapy failure, ECOG ≤2, and adequate organ function. Exclusions include recent anticancer treatments (within 4 weeks), active infections, uncontrolled autoimmune diseases, QTcF ≥480 ms, pregnancy, or live vaccines within 30 days. Contraception is required during and post-treatment (9.5 months for females, 6.5 months for males).

   Click to Show/Hide
Administration Dosage
ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
Related Clinical Trial
NCT Number NCT06041516  Clinical Status PHASE1
Clinical Description A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Primary Endpoint
The study aims to determine the maximum tolerated dose (MTD) of ADCT-701 by assessing dose-limiting toxicities (DLTs) during Cycle 1 (Days 1-21), with adverse events (AEs) categorized by type and severity grade.
Other Endpoint
Safety evaluations include monitoring AEs through 30 days post-treatment, while efficacy is assessed via overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) over 5 years. Pharmacokinetic (PK) analysis measures PBD-conjugated antibody, total antibody, and unconjugated warhead SG3199 for up to 2 years, alongside immunogenicity testing for anti-drug antibodies (ADAs).

   Click to Show/Hide
References
Ref 1 ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
Ref 2 Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas